[{"id":"2e2ffa16-9364-47ec-af17-c174c6bba967","acronym":"ARISTOCRAT","url":"https://clinicaltrials.gov/study/NCT05629702","created_at":"2022-11-29T14:57:14.668Z","updated_at":"2024-07-02T16:34:25.626Z","phase":"Phase 2","brief_title":"ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids","source_id_and_acronym":"NCT05629702 - ARISTOCRAT","lead_sponsor":"University of Birmingham","biomarkers":" MGMT","pipe":" | ","alterations":" IDH wild-type","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Sativex (nabiximols)"],"overall_status":"Recruiting","enrollment":" Enrollment 234","initiation":"Initiation: 02/03/2023","start_date":" 02/03/2023","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2024-06-17"}]